• CB-839 Workflow for Cancer Metabolism

  2026-09-03

  CB-839, also called Telaglenastat, enables direct pharmacologic testing of GLS1 dependence across viability, metabolite, autophagy, and combination assays. This workflow connects practical glutaminolysis inhibition with the spliceosomal and metabolic vulnerabilities reported in MYCN-amplified neuroblastoma.

• SORL1 Deficiency Reshapes Neuronal and Microglial ELN

  2026-09-03

  This reference article highlights that SORL1 deficiency does not produce a uniform endo-lysosomal defect across human neural cell types. Instead, neurons show prominent stress in early and recycling endosomes, whereas microglia preferentially exhibit lysosomal stress, providing a cell-type framework for Alzheimer’s disease research and therapeutic interpretation.

• Hexose Diphosphate: From Flux to Translation

  2026-09-02

  Hexose diphosphate is more than a glycolytic reagent: it is a practical perturbation tool for connecting carbohydrate metabolism, ischemic energy failure, and inflammation biology. This thought-leadership guide places the metabolite alongside new evidence on phosphoenolpyruvate and cGAS–STING signaling, while separating established product utility from translational hypotheses that require validation.

• BRD4–RAC1 Cotargeting in Breast Cancer

  2026-09-02

  The reference study identifies combined BRD4 and RAC1 inhibition as a context-dependent strategy that limits growth, migration, stem-like properties, and tumorigenesis across major breast cancer subtypes. Its mechanistic contribution is the linkage of BRD4–RAC1 blockade to disruption of the c-MYC–G9a–FTH1 axis and suppression of HDAC1-associated chromatin regulation.

• Trichostatin A (TSA) Workflows in Cancer Research

  2026-09-01

  Trichostatin A (TSA) converts HDAC activity into a measurable experimental variable, linking histone acetylation with proliferation, differentiation, and transcriptional control. This practical guide covers cell-based workflows, breast cancer assays, interpretation of the CBX2–RACK1–HDAC1 study, and troubleshooting for reproducible epigenetic experiments.

• Propranolol Rewires Metabolism After Severe Burns

  2026-09-01

  This phase II randomized trial links propranolol treatment after severe burn injury to coordinated changes in adipose-tissue metabolomics, lipid composition, hormone-sensitive lipase signaling, and endoplasmic reticulum stress. The findings provide a mechanistic framework in which beta-adrenergic blockade reduces catecholamine-driven hypermetabolism and shifts lipid signaling toward a less inflammatory state.

• Relative Viability and Cell Death in Cancer Drug Testing

  2026-08-31

  Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework that separates growth inhibition from cell killing while accounting for differences in response magnitude and timing, improving the interpretation and design of in vitro cancer assays.

• Tunable Human Intestinal Organoids: Study Insights

  2026-08-31

  The reference study develops a human small intestinal organoid system that maintains strong proliferation while expanding cellular diversity under a single culture condition. Its central innovation is to strengthen stemness first, then tune lineage outcomes through BET, Wnt, Notch, and BMP signaling rather than recreating complex spatial gradients.

• QSHXO Mechanisms in MASLD: Autophagy and Ferroptosis

  2026-08-30

  A 2026 World Journal of Hepatology study reports that Qushi Huoxue ointment improves lipid accumulation and inflammatory injury in an MCD diet-induced mouse model of MASLD. Its central contribution is a coordinated mechanistic framework linking enhanced autophagy with Nrf2-associated suppression of ferroptosis, while also identifying important limits for causal interpretation and translation.

• 3-Hydroxybutyrate (BHBA) Assay Workflows

  2026-08-29

  Use 3-hydroxybutyrate (BHBA) as a controlled ketone-body add-back to model ketosis, test ferroptosis resistance, and connect metabolic state with chromatin regulation. This workflow translates stroke-neuroprotection findings into practical cell assays while separating direct BHBA effects from whole-body conditioning responses.

• Ran Lactylation, SIRT1, and Astrocyte Polarization

  2026-08-28

  A 2026 International Immunopharmacology study identifies non-histone Ran lactylation at lysine 123 as a metabolic mechanism linking lactate accumulation to STAT3 nuclear transport and A2-like astrocyte polarization after oxygen-glucose deprivation/reoxygenation. Its combination of lactate manipulation, Ran genetics, biochemical analysis, and spinal cord injury modeling provides a framework for studying lactylation-dependent repair responses while highlighting unresolved questions about SIRT1 regulation.

• Dynamic Chromatin Programs in Perinatal Cardiomyocytes

  2026-08-28

  The reference study maps how chromatin accessibility, long-range regulatory contacts, and gene expression change as cardiomyocytes transition from fetal to neonatal states. Its identification of MEF2- and AP1-centered regulatory programs provides a framework for interpreting maturation defects and improving the electrophysiological properties of iPSC-derived cardiomyocytes.

• Reproducible iPSC-to-RGC Differentiation

  2026-08-27

  The reference study presents a chemically defined strategy that combines dual SMAD and canonical Wnt inhibition to produce retinal ganglion cells from induced pluripotent stem cells with improved consistency. Its staged differentiation and CD90.2-based enrichment workflow offers a practical foundation for glaucoma modeling, RGC biology, and reproducible cell-based experiments.

• Resazurin Cell Viability Assay Kit in Bone Research

  2026-08-27

  The Resazurin Cell Viability Assay Kit provides a sensitive cell viability assay for separating treatment-related cytotoxicity from altered osteoblast activity. This article shows how resazurin data can strengthen mechanistic studies of PORCN inhibition and sclerosteosis while clarifying important metabolic-readout limitations.

• SP2509: Lysine-Specific Demethylase 1 Antagonist

  2026-08-26

  SP2509 is a selective LSD1 antagonist for connecting chromatin remodeling to apoptosis, differentiation, and colony suppression in acute myeloid leukemia models. This practical guide covers formulation, dose-response design, H3K4Me3 readouts, combination studies, and troubleshooting for reproducible cancer epigenetics research.

8041 records 6/537 page Previous Next First page 上5页 678910 下5页 Last page